JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained (Q58289362)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

acute myeloid leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Scott H Kaufmann

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

R F McClure

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J E Karp

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

T L Lasho

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

H L Powell

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

G W DeWald

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Tefferi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

971-978

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

cites work

The Janus kinases (Jaks)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Series introduction. JAK-STAT signaling in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Constitutive activation of STAT transcription factors in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Activated Stat related transcription factors in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Constitutive activation of Stat1 and Stat3 in primary erythroleukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Essential thrombocythaemia: challenges and evidence-based management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

On the molecular origins of the chronic myeloproliferative disorders: it all makes sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Jak2 tyrosine kinase: a true jak of all trades?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Reutilization of Immunoblots after Chemiluminescent Detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Clonality in the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Myelodysplasia with fibrosis: a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Opposing effects of PML and PML/RAR alpha on STAT3 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

The JAK2 V617F mutation in de novo acute myelogenous leukemias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

Myeloproliferative disorders terminating in acute megakaryoblastic leukemia with chromosome 3q26 abnormality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

Myelodysplastic syndrome with myelofibrosis: myelodysplastic syndrome as a major primary disorder for acute myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

Acute megakaryoblastic leukaemia or acute myelofibrosis?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

Both proteasomes and lysosomes degrade the activated erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404206

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598306%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference